Comparative risk of infections with GLP-1 receptor agonists versus SGLT2 inhibitors in patients with advanced chronic kidney disease and type 2 diabetes

Key Points

• Infection risk varies between GLP-1 receptor agonists and SGLT2 inhibitors in chronic kidney disease patients, indicating a need for careful treatment selection.
• The analysis highlights the potential differential impact on infection rates with these two classes of diabetes medications.
• Observational analysis of patients with advanced chronic kidney disease reveals insights into medication-related infection risks.
• This study emphasizes the importance of understanding treatment risks, especially for diabetes management in chronic kidney disease patients.